SecBot SecBot

STRO

SUTRO BIOPHARMA, INC.
Nasdaq· Biological Products, (No Diagnostic Substances)· CIK 0001382101 Biotech & Drug Discovery
$9.32 −0.50 (−5.09%)
Nov 16 4:00 PM ET · prev $9.82
Market cap
$159.2M
Micro cap
Consensus
Buy
90% Buy or better · 20 analysts
Median target
🔒 Subscribers only
1 year
+9.6%
from $8.50 · Nov 17
30 days
−17.2%
from $11.26
52-week range
$7.30–40.91
−77% from high · low Dec 2
Avg volume 20D
329.3K
shares / day
Short interest
2.26M
≈13.6% of shares · +15.1%
Days to cover
6.3
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
6
analyzed by SecBot
SecBot read BEARISH 2 reports · 90 days
Balance 1 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/2

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q3 2026: 16 added (0 new), 11 trimmed or exited.

  • AnalystsBULLISH

    18 of 20 rate it Buy or better.

  • Short sellersBUILDING

    Short interest +15.1% to 2.26M shares. 6.3 days to cover, ≈13.6% of shares.

  • TrendDOWNTREND

    28% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
Qube Research & Technologies LtdDOUBLED379,290$6.1M
MARSHALL WACE, LLPADD317,964$5.1M
VANGUARD PORTFOLIO MANAGEMENT LLCADD282,764$4.6M
JPMORGAN CHASE & COADD225,840$3.6M
FMR LLCDOUBLED171,245$2.8M
UBS Group AGTRIM115,058$1.9M
MACKENZIE FINANCIAL CORPTRIM68,513$1.1M
BNP PARIBAS FINANCIAL MARKETSDOUBLED62,306$1.0M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

20 analysts
Buy 90% rate it Buy or better
Strong Buy6Buy12Hold1Sell1Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Nov 13, 2026Barclays
MAINTAIN
MAINTAINOverweight
Oct 15, 2026Wedbush
REITERATE
REITERATEOutperform
Aug 13, 2026Citizens
MAINTAIN
MAINTAINMarket Outperform
Aug 13, 2026Wedbush
REITERATE
REITERATEOutperform
May 28, 2026Barclays
INITIATE
INITIATEOverweight

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Sep 18, 2026
Gerber Hans-Peter
CHIEF SCIENTIFIC OFFICER
Sep 18, 2026
TAX W/H$20.6K
Sep 18, 2026
Gerber Hans-Peter
CHIEF SCIENTIFIC OFFICER
Sep 18, 2026
EXERCISE3,750 sh
Jun 5, 2026
MATSUI CONNIE
Director
Jun 5, 2026
AWARD10,000 sh
Jun 5, 2026
Dybbs Michael
Director
Jun 5, 2026
AWARD10,000 sh
Jun 5, 2026
Hunter Heidi
Director
Jun 5, 2026
AWARD10,000 sh
Jun 5, 2026
Jagpal Sukhi
Director
Jun 5, 2026
AWARD10,000 sh
Jun 5, 2026
Lobacki Joseph M
Director
Jun 5, 2026
AWARD10,000 sh
Jun 5, 2026
PANEK JAMES P
Director
Jun 5, 2026
AWARD10,000 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
2,257,487
shares short
+15.1%
vs prior settlement
6.3
days to cover
≈13.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 12, 2026 SEC
Sutro Biopharma reported Q3 2026 revenue of $9.1M (below the $14.1M consensus) and GAAP EPS of -$1.90 (better than the…
PRESS-RELEASE · Impact 5/10
Nov 12, 2026 Earnings
Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
STRO-004, TF-targeting ADC, Phase 1 STRIVE-01 study advancing; next clinical update and initiation o
Nov 9, 2026 SEC
Coastlands Capital LP disclosed a new 5.14% passive stake in Sutro Biopharma, holding 852,669 shares as of November 5…
SC 13G · Impact 3/10
Sep 30, 2026 Inst.
Qube Research & Technologies · DOUBLED
379,290 shares ($6.1M)
Sep 30, 2026 Inst.
MARSHALL WACE, LLP · ADD
317,964 shares ($5.1M)
Sep 18, 2026 Insider
Gerber Hans-Peter surrendered for taxes 1,345 shares
CHIEF SCIENTIFIC OFFICER @ $15.34 ($20.6K)
Sep 18, 2026 Insider
Gerber Hans-Peter acquired via exercise 3,750 shares
CHIEF SCIENTIFIC OFFICER
Aug 12, 2026 SEC
Sutro Biopharma reported Q2 2026 revenue of $9.8M (vs $63.7M YoY) and a net loss of $38.5M (EPS -$2.33 vs -$1.35 YoY)…
8-K · Impact 7/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Recent

SecBot reports

6 filings · 2 press releases · 1 bullish · 2 bearish · 1 mixed · 2 neutral
All STRO filing & press-release reports (8)